Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Edgewise Therapeutics Inc

EWTX
Current price
13.45 USD +0.47 USD (+3.62%)
Last closed 11.83 USD
ISIN US28036F1057
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 414 146 432 USD
Yield for 12 month -10.81 %
1Y
3Y
5Y
10Y
15Y
EWTX
21.11.2021 - 28.11.2021

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado. Address: 1715 38th Street, Boulder, CO, United States, 80301

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

42.78 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-1 732 000 USD

Current Quarter

+1 059 000 USD

Last Quarter

Key Figures EWTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -156 763 008 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -24.01 %
PEG Ratio
Return On Equity TTM -34.40 %
Wall Street Target Price 42.78 USD
Revenue TTM
Book Value 4.84 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.45 USD
Diluted Eps TTM -1.45 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics EWTX

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History EWTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio
Last Split Date

Stock Valuation EWTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -2.60
Price Book MRQ 3.08

Financials EWTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators EWTX

For 52 weeks

10.60 USD 38.12 USD
50 Day MA 22.35 USD
Shares Short Prior Month 9 088 389
200 Day MA 25.18 USD
Short Ratio 6.80
Shares Short 10 387 232
Short Percent 15.91 %